Abstract
Levodopa administration is currently the most common treatment to alleviate Parkinson’s Disease (PD) symptoms. Nevertheless, prolonged use of Levodopa leads to a wearing-off (WO) phenomenon, causing symptoms to reappear. To build a personalized treatment plan aiming to manage PD and its symptoms effectively, there is a need for a technological system able to continuously and objectively assess the WO phenomenon during daily life. In this context, this paper proposes a WO tracker able to exploit neuromuscular data acquired by a dedicated wireless sensor network to discriminate between a Levodopa benefit phase and the reappearance of symptoms. The proposed architecture has been implemented on a heterogeneous computing platform, that statistically analyzes neural and muscular features to identify the best set of features to train the classifier model. Eight models among shallow and deep learning approaches are analyzed in terms of performance, timing and complexity metrics to identify the best inference engine. Experimental results on five subjects experiencing WO, showed that, in the best case, the proposed WO tracker can achieve an accuracy of ~84%, providing the inference in less than 41 ms. It is possible by employing a simple fully-connected neural network with 1 hidden layer and 32 units.
Subject
Electrical and Electronic Engineering,Biochemistry,Instrumentation,Atomic and Molecular Physics, and Optics,Analytical Chemistry
Reference29 articles.
1. Chronological View of Peak and Diphasic Dyskinesia, Wearing off and Freezing of Gait in Parkinson’s Disease;Kim;J. Park. Dis.,2019
2. Identification of motor and nonmotor wearing-off in Parkinson’s disease: Comparison of a patient questionnaire versus a clinician assessment;Stacy;Mov. Disord. Off. J. Mov. Disord. Soc.,2005
3. Assessment of Wearing Off in Parkinson’s disease using objective measurement;Farzanehfar;J. Neurol.,2021
4. Wearing-off scales in Parkinson’s disease: Critique and recommendations;Antonini;Mov. Disord.,2011
5. A blinded, controlled trial of objective measurement in Parkinson’s disease;Woodrow;Npj Park. Dis.,2020